Atara Biotherapeutics (ATRA): Another Dip Buying Opportunity Following CRL For CMC Issues

This article was written by Follow Background: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long…

Calidi Biotherapeutics CEO Allan Camaisa sells $16,200 in stock By Investing.com

SAN DIEGO—Allan Camaisa, CEO and Chairman of the Board at Calidi Biotherapeutics, Inc. (NASDAQ:CLDI), recently sold…

Protalix BioTherapeutics’ Phase 1 Data Bolsters Gout Aspirations

This article was written by Follow I’m a stock analyst with an MBA and a background…